GlassScriptPhysician profile
Aissa T Alexeeva
NPI 1093799876
$2,751.56
in general payments reported to CMS, 2019-2025
26 companies · $991 in 2025
The $991 reported for 2025 was more than what a typical Epilepsy provider received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $182 · 2021: $223 · 2022: $418 · 2023: $356 · 2024: $369 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,185.34 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Novartis Pharmaceuticals Corporation | $181.92 | 2019-2025 | |
| Pfizer INC. | $176.65 | 2023-2025 | |
| Allergan, INC. | $168.33 | 2020-2022 | |
| Axsome Therapeutics, INC. | $138.12 | 2025 | Symbravo |
| Argenx US, INC. | $121.71 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Medtronic, INC. | $118.13 | 2024-2025 | Percept PC Brainsense, Inceptiv |
| Teva Pharmaceuticals USA, INC. | $114.84 | 2022-2025 | Ajovy, Austedo Xr |
| Lilly USA, LLC | $76.65 | 2019-2025 | Kisunla, Amyvid |
| Eisai INC. | $76.36 | 2025 | |
| Neurocrine Biosciences, INC. | $62.98 | 2025 | |
| Boston Scientific Corporation | $35.92 | 2025 | General - Dbs |
| Globus Medical, INC. | $34.89 | 2025 | Senza |
| Alexion Pharmaceuticals, INC. | $31.27 | 2019-2025 | Ultomiris |
| Biogen, INC. | $29.15 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $28.14 | 2025 | |
| Lundbeck LLC | $22.90 | 2021 | |
| Grifols USA, LLC | $20.95 | 2025 | Gamunex-C |
| Amylyx Pharmaceuticals, INC. | $19.43 | 2023 | Relyvrio |
| Astrazeneca Pharmaceuticals LP | $18.96 | 2025 | |
| Ucb, INC. | $18.47 | 2025 | Rystiggo |
| Horizon Therapeutics Plc | $16.42 | 2022 | |
| Acorda Therapeutics, INC | $14.53 | 2019 | |
| Greenwich Biosciences, INC. | $14.05 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.04 | 2021 | |
| Emd Serono, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aissa Alexeeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.